



Conference on ‘PUFA mediators: implications for human health’ Symposium 1: PUFA: health effects and health claims

Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline

Marie Hennebelle^{1,2}, Mélanie Plourde^{1,2,3}, Raphaël Chouinard-Watkins^{1,2},
Christian-Alexandre Castellano^{1,2}, Pascale Barberger-Gateau⁴ and Stephen C.unnane^{1,2,3*}

¹Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada,

²Physiology and Biophysics, Université de Sherbrooke, Sherbrooke, QC, Canada,

³Departments of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada

⁴INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France

Epidemiological studies fairly convincingly suggest that higher intakes of fatty fish and *n*-3 fatty acids are associated with reduced risk of Alzheimer’s disease (AD). DHA in plasma is normally positively associated with DHA intake. However, despite being associated with lower fish and DHA intake, unexpectedly, plasma (or brain) DHA is frequently not lower in AD. This review will highlight some metabolic and physiological factors such as ageing and *apoE* polymorphism that influence DHA homeostasis. Compared with young adults, blood DHA is often slightly but significantly higher in older adults without any age-related cognitive decline. Higher plasma DHA in older adults could be a sign that their fish or DHA intake is higher. However, our supplementation and carbon-13 tracer studies also show that DHA metabolism, e.g. transit through the plasma, apparent retroconversion and β -oxidation, is altered in healthy older compared with healthy young adults. *ApoE4* increases the risk of AD, possibly in part because it too changes DHA homeostasis. Therefore, independent of differences in fish intake, changing DHA homeostasis may tend to obscure the relationship between DHA intake and plasma DHA which, in turn, may contribute to making older adults more susceptible to cognitive decline despite older adults having similar or sometimes higher plasma DHA than in younger adults. In conclusion, recent development of new tools such as isotopically labelled DHA to study DHA metabolism in human subjects highlights some promising avenues to evaluate how and why DHA metabolism changes during ageing and AD.

Alzheimer’s disease: Docosahexaenoic acid: Ageing: ApoE: Cognition

The cognitive and psychological health of older adults is now a major preoccupation for healthcare services and researchers alike. Alzheimer’s disease (AD) is the main form of cognitive decline in older persons in Western countries⁽¹⁾. Age is the main risk factor associated with AD⁽¹⁾, but other factors also have an effect such as a pre-disposing genetic polymorphism, i.e. $\epsilon 4$ allele of *apoE4*⁽²⁾, vascular risk factors including hypertension, obesity and type 2 diabetes⁽¹⁾, and lifestyle including physical activity and dietary habits^(3,4). Among the nutrients closely associated with brain function, the *n*-3 fatty acids, especially

DHA, have attracted special attention. Fatty fish and seafood are the most important dietary sources of both DHA and EPA. DHA is by far the predominant *n*-3 fatty acid in the brain and is present mostly in various membrane phospholipids (PL) of neurons, especially in synapses⁽⁵⁾. In contrast to other common dietary long-chain fatty acids, DHA is highly conserved and poorly β -oxidised^(6–8). In human subjects, DHA synthesis is relatively inefficient, especially in comparison to rodents⁽⁹⁾.

Low intake of *n*-3 fatty acids has long been associated with higher risk of CVD⁽¹⁰⁾, and also of suboptimal brain

Abbreviations: AD, Alzheimer’s disease; CE, cholesteryl esters; ¹³C-DHA, carbon-13 labelled DHA; PL, phospholipids.

*Corresponding author: Professor S.C. Cunnane, fax (+1) 819-829-7141, email Stephen.Cunnane@USherbrooke.ca

development⁽¹¹⁾. Much effort has been focused over the past decade on whether a higher DHA intake could decrease the risk of cognitive decline in older adults, or reduce the progression from mild cognitive impairment towards AD. In general, these studies polarise in two directions: randomised clinical trials that are largely negative and epidemiological studies that are more positive⁽¹²⁾ about the DHA's role in maintaining cognition during ageing. Thus, in general, DHA supplementation trials in AD (with or without EPA) have not so far produced any truly positive results^(12–15). Methodological issues such as dose of *n*-3 fatty acid, duration of treatment or selection criteria may well have affected the outcomes of these trials. DHA supplementation may have a greater positive effect on memory and learning in healthy adults⁽¹⁶⁾, elderly with subjective cognitive complaints⁽¹⁷⁾ or with mild cognitive impairment⁽¹⁸⁾ than in those with AD^(12,14,19). However, prospective epidemiological studies have been more positive; they broadly show that habitually low intake of fish and/or DHA is associated with higher risk of developing AD^(12,20,21). These results are supported by the neuroprotective role of DHA reported for non-human models of neurodegenerative disease^(22–26).

Studies with biological samples (human blood and brain) may be able to provide useful leads to explain the divergent results between randomised clinical trials and epidemiological studies. We have previously reviewed at some length the methodological limits on observational or intervention studies on DHA supplementation in older adults or in AD^(12–15,20,21,27); so we will review them here only briefly. We will also present an emerging framework showing that DHA homeostasis changes in older adults and differs in carriers from non-carriers of *apoE4*, probably before the onset of cognitive decline.

DHA in plasma and post-mortem human brain

Brain DHA

In primate, pig and rodent models, when *n*-3 intake is severely deficient for extended periods, brain DHA also decreases across all cell types and regions, in association with lower scores on cognitive and behavioural tests^(25,28–31). AD is now widely associated with lower fish and DHA intake, so it would be logical that post-mortem brain samples of patients with a definitive diagnosis of AD also contained lower DHA. Indeed, in the hippocampus, which is central to memory processing and learning, AD patients reportedly do have lower DHA^(32,33). However, in the temporal and frontal cortices which are also affected in AD, DHA is almost always the same as in the controls (Fig. 1). Studies reporting lower DHA in the AD brain show that other fatty acids are also lower, particularly *n*-6 PUFA^(35,41,44,46). Thus, the effect of AD is not specific to DHA which is contrary to what would be expected if only *n*-3 fatty acid intake were deficient.

There are many potential methodological reasons for the observed lack of agreement between the apparently




Fig. 1. Summary of the published literature on brain and blood DHA in Alzheimer's disease. The symbols represent the results of individual studies using each study's control group as the reference (100 %; dotted line). The papers from which these DHA data are obtained are as follows: A, Arsenault *et al.*⁽³⁴⁾; B, Astarita *et al.*⁽³⁵⁾; C, Boston *et al.*⁽³⁶⁾; D, Brooksbank *et al.*⁽³⁷⁾; E, Cherubini *et al.*⁽³⁸⁾; F, Conquer *et al.*⁽³⁹⁾; G, Corrigan *et al.*⁽⁴⁰⁾; H, Corrigan *et al.*⁽⁴¹⁾; I, Cunnane *et al.*⁽⁴²⁾; J, Fraser *et al.*⁽⁴³⁾; K, Guan *et al.*⁽⁴⁴⁾; L, Laurin *et al.*⁽⁴⁵⁾; M, Prasad *et al.*⁽⁴⁶⁾; N, Selley *et al.*⁽⁴⁷⁾; O, Skinner *et al.*⁽⁴⁸⁾; P, Söderberg *et al.*⁽³²⁾; Q, Tully *et al.*⁽⁴⁹⁾. F,T,P, frontal, temporal and/or parietal cortex; P-H, para-hippocampus; H, hippocampus; P-TFA, plasma total fatty acids; P-PL, plasma phospholipids; P-CE, plasma cholesteryl esters; RBC, red blood cells.

low DHA intakes in AD yet frequently normal DHA levels in the brain⁽¹²⁾. Crucial among these are the 'healthy' controls against which the AD cases are compared as well as the very marked extent of regional brain atrophy associated with ageing regardless of the presence of neurological disease^(44,50). Furthermore, the basis for classifying a patient as having AD, i.e. whether on clinical cognitive criteria or on neuropathological score, may not give consistent results since senile plaques are increasingly recognised as being present in a significant proportion of cognitively normal elderly persons^(51–53). Hence, there is a risk that post-mortem samples from brain banks for which cognitive status is not known at the time of death could be misclassified if based solely on neuropathological scores. It also appears that membrane PL in the cortex can tenaciously retain DHA and that a more discrete and specific subcellular pool or membrane pool of DHA may have to be measured⁽⁴³⁾. Brain membrane DHA cycles rapidly between PL and free DHA via DHA-CoA^(54,55), and the deteriorating efficacy of this process could theoretically contribute to the neurodegenerative processes. Thus, the key issue in relation to post-mortem tissue analysis is that the time to lipid extraction is rarely less than 4–5 h yet DHA turnover is on the order of minutes, if not seconds. Since the turnover of DHA towards resolvins and neuroprotectins are orders of magnitude lower than the amount of DHA in the brain NEFA pool, truly 'physiological' amounts of these products are extremely difficult to measure, especially in human subjects^(23,56). As also noted elsewhere, these and other issues severely constrain the validity and hence the utility of DHA measurements on human post-mortem brain samples⁽⁵⁷⁾.

Blood DHA

Lower DHA would normally be expected in the blood of those with habitually low DHA intake (whether diagnosed with AD or not). In some AD studies, lower DHA is indeed reported for plasma total lipids⁽³⁸⁾, PL^(39,40,42), cholesteryl esters⁽⁴⁹⁾ and NEFA⁽⁵⁸⁾. However, many other AD studies show no difference in plasma DHA, whether in PL or total fatty acids^(34,38,42,45,59). Some even report higher DHA in plasma PL⁽⁴⁵⁾ or cholesteryl esters (CE)^(40,42). Similar inconsistencies are present across DHA levels reported for the erythrocytes in AD (Fig. 1)^(36,40,47). Prospective studies also show this inconsistency: some found a strong association between lower blood DHA level and slower cognitive decline⁽⁶⁰⁾ or lower risk of dementia⁽⁶¹⁾, whereas other did not^(45,59,62). It may be that the cognitive domain studied^(63,64) and *apoE4* genotype^(65,66) contribute to this scatter in the data.

DHA homeostasis during ageing and apoE

We propose that even when collected under hypothetically ideal conditions (zero delay; perfectly matched, cognitively healthy controls, etc.), data obtained from single blood samples are too limited to fully understand possible changes in DHA metabolism due to genotype, ageing or neurodegenerative disease. However, isotopically labelled DHA is emerging as a useful tool to assess how the metabolism of DHA changes with age. Indeed, in a relatively simple study design, it was clear that the clearance of a 50mg oral dose of uniformly carbon-13 labelled DHA (¹³C-DHA) from the blood over 1 month was much slower in healthy 76-year-old compared with 27-year-old adults⁽⁶⁷⁾. These results were similar to our earlier report that the increase in plasma DHA during a short-term treatment with fish oil was higher in healthy older persons⁽⁶⁸⁾. ¹³C-DHA enrichment in plasma NEFA and TAG of older adults was most affected (four- to fivefold higher than in the young adults) but its enrichment in PL and CE ¹³C-DHA was also affected. The doubling of ¹³C-DHA enrichment in plasma PL and CE emerged only after about 7 d post-dose, suggesting slower DHA clearance through plasma lipid classes, i.e. an altered plasma 'DHA wave' in older adults (Fig. 2)⁽⁶⁷⁾.

Clearly, therefore, healthy ageing seems to change DHA metabolism and, hence, homeostasis in human subjects. Notwithstanding the limited extent to which the kinetic behaviour of a tracer can be compared with a single plasma fatty acid measurement, the difference in ¹³C-DHA homeostasis in the elderly seems to reflect the results observed in two studies in which lower DHA was reported in plasma PL yet higher DHA was reported in plasma CE of AD patients^(40,42). The minimally invasive nature of this type of experiment makes it difficult to invoke a particular mechanism but one could speculate that the changing sensitivity of endothelial lipoprotein lipase could be involved in this age-associated difference in DHA homeostasis⁽⁶⁹⁾.




Fig. 2. Delayed plasma clearance of carbon 13-labelled DHA (¹³C-DHA) during healthy ageing, adapted from Plourde *et al.*⁽⁶⁷⁾. Plasma ¹³C-DHA concentration was followed over 28 d after the oral administration of a single 50 mg dose of ¹³C-DHA in young (27 years; *n* 6) and elderly (76 years; *n* 6) participants. In older adults, plasma tracer concentration in NEFA and TAG was four to fivefold higher 4 h after giving the oral dose and about twofold higher 1–4 weeks later in phospholipids (PL) and cholesteryl esters (CE).

ApoE4 carriers are at significantly higher risk of AD^(70,71). It is now emerging that the *apoE4* status also affects DHA metabolism in human subjects^(27,72,73). This interaction may help explain why the protective association of higher dietary intake of fish^(74,75) or higher erythrocyte total *n*-3 fatty acids⁽⁶⁵⁾ is generally limited to non-carriers of *apoE4*. Measuring expired ¹³C-CO₂ after dosing with ¹³C-DHA permits the estimation of the whole body half-life of DHA in healthy older adults, which is of the order of 32 d in carriers of *apoE4* and 140 d in non-carriers of *apoE4*⁽⁷²⁾. Ageing seems not to affect the whole body half-life of DHA although the small sample size makes these results still somewhat preliminary⁽⁶⁷⁾.

Using positron emission tomography and the tracer, ¹¹C-DHA, human brain turnover of DHA has been estimated to be about 4 mg/d, giving rise to a half-life of brain DHA of about 2.5 years⁽⁵⁴⁾. Hence, the half-life of brain DHA is much longer than its whole body half-life. Perhaps further assessments of the brain or whole body half-life of DHA could provide some insight into the current ineffectiveness of DHA supplements in AD despite the fact that these supplements typically supply several fold the brain's apparent daily turnover of DHA⁽¹²⁾.

ApoE4 seems also to suppress the plasma DHA response to a fish oil supplement⁽⁷³⁾ and the metabolism of an oral dose of ¹³C-DHA⁽⁷²⁾, an effect somewhat opposite to that observed with healthy ageing. For up to 28 d after a single oral dose of ¹³C-DHA, carriers of *apoE4* have a slightly lower concentration of plasma ¹³C-DHA compared with non-carriers⁽⁷²⁾. When the tracer is given both before and again after a 5-month period




Fig. 3. Plasma carbon 13-labelled DHA (^{13}C -DHA) concentration over 28 d after a single oral dose of 40 mg ^{13}C -DHA. Results expressed as means (SEM) show the plasma ^{13}C -DHA status (a) pre- ($n=6$) and (b) post- ($n=4$) supplementation of 5 months with 1.8 g/d EPA + 1.4 g/d DHA in apoE $\epsilon 4$ carriers (apoE4+; \circ) and non-carriers (apoE4-; \bullet).

of DHA+EPA supplementation, the apoE4 carriers had a greater accumulation of the tracer in plasma after supplementation compared with the non-carriers, again suggesting slower clearance of DHA to and/or use by tissues (Fig. 3). Hence, two established risk factors for AD (ageing and apoE4) both significantly change DHA homeostasis but possibly in different ways.

Linking dietary and plasma DHA

Habitual DHA intake is commonly estimated to be <250 mg/d^(76–78) but this is a difficult and laborious measurement and subject to high day-to-day variability depending on the frequency of fish or shellfish consumption. Hence, it would be useful if DHA intake and plasma DHA were highly correlated because plasma DHA measurement is now technically simple and reliable, so it could potentially be a surrogate for dietary DHA measurement. There is indeed a good positive correlation between dietary and plasma intake for DHA consumption, especially at DHA intakes towards 1000 mg/d, during which plasma DHA rises to a maximum of about 4% in plasma total lipids. However, DHA always seems to be present in plasma, even when DHA intake is negligible; thus, vegans consuming no known dietary sources of DHA still have about 0.5% DHA in plasma total lipids⁽⁷⁹⁾. The problem is that there are relatively few reports on which to build the relationship of dietary to plasma DHA. At DHA intakes between 0 and 50 mg/d, DHA is between 0.5 and 1.2% of plasma total lipids, but the spread in these data is large⁽⁵⁷⁾. A value of 0.5% DHA in plasma total lipids therefore seems to be at or close to the lower limit possible of plasma DHA in healthy adults.

The AD cases we have studied had 1.0% DHA in plasma total lipids, which empirically corroborates very low DHA intake, yet they had ‘normal’ DHA in the PL of brain cortical grey matter⁽⁴²⁾. Plasma DHA does not rise in human subjects given EPA or α -linolenic acid supplements, even in vegans^(80–82). The conundrum therefore is: how are plasma (or brain) DHA levels maintained when DHA intakes are very low to negligible? We speculate that with changes in DHA metabolism and homeostasis during age-related cognitive decline, the

diet–plasma relation of DHA may shift, explaining why with lower DHA intake, a population with age-related cognitive decline appears to have the same plasma DHA concentration as healthy elderly even though the availability of DHA to the tissues may be reduced⁽⁸³⁾. The lack of an established reference lipid class in blood (PL, CE, TAG or NEFA, erythrocytes, etc.) for DHA measurements relative to intake still hampers the extent to which plasma DHA data from various reports can be compared in relation to ageing, genotype and risk of cognitive decline. This area clearly needs further research but suffice it to say that it is becoming increasingly important to take into account changing DHA homeostasis in the study of ageing population, especially in a context of age-related cognitive decline or AD.

Conclusion

We have sought to briefly highlight some of the methodological challenges and potential future directions for the study of DHA in ageing and AD. The emerging evidence for changing DHA half-life in older adults and in carriers of apoE4 should encourage more basic research on DHA metabolism in human subjects. Molecular, cellular and animal models have contributed enormously to understanding the complexity of DHA biology, but none of them seem to represent the changes in DHA homeostasis reported in elderly human subjects. The human brain is able to strongly retain DHA in membrane PL despite very low DHA intake and advanced AD⁽⁴²⁾, so the classical dietary n -3 deficiency model used to probe the function of DHA in the animal brain appears inappropriate for research into AD. In human subjects, DHA in the post-mortem brain is unlikely to correctly reflect what is happening during ageing and AD, due to its fast turnover in neuronal membrane PL. Ageing- and apoE4-associated changes in DHA metabolism strongly suggest altered DHA homeostasis involving a decrease in plasma DHA clearance during age-related cognitive decline and AD. Therefore, a shift in the relationship between plasma and dietary DHA may be occurring during age-related cognitive decline and AD, one that needs to be considered when looking at plasma DHA as a measure of dietary DHA intake. In the future, the availability of innovative tools for studies of DHA half-life and metabolism in human subjects will be needed to understand in a better manner the changes in DHA metabolism occurring during human ageing and AD and the potential protective role of DHA on cognitive decline. As shown in prospective studies, a protective role of DHA in cognitive health of older persons may depend on consuming a healthy diet throughout adult life.

Acknowledgements

Mélanie Fortier, Conrad Filteau, Christine Rioux-Perreault, Jennifer Tremblay-Mercier and Sébastien Tremblay provided excellent technical support.

Financial Support

CIHR, NSERC, FQRNT (CFQCU), INSERM, CFI and CRC provided financial support for S. C. C.'s research.

Conflicts of Interest

None.

Authorship

M. H. and S. C. C. conceived and wrote the first draft with all the authors contributing to the revisions and final version of the manuscript.

References

1. Blennow K, de Leon MJ & Zetterberg H (2006) Alzheimer's disease. *Lancet* **368**, 387–403.
2. Corder EH, Saunders AM, Strittmatter WJ *et al.* (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923.
3. Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. *Nat Rev Neurosci* **9**, 568–578.
4. Alles B, Samieri C, Feart C *et al.* (2012) Dietary patterns: a novel approach to examine the link between nutrition and cognitive function in older individuals. *Nutr Res Rev* **25**, 207–222.
5. Crawford MA, Bloom M, Broadhurst CL *et al.* (1999) Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. *Lipids* **34**, Suppl, S39–S47.
6. Cunnane SC, Ryan MA, Nadeau CR *et al.* (2003) Why is carbon from some polyunsaturates extensively recycled into lipid synthesis? *Lipids* **38**, 477–484.
7. Gavino GR & Gavino VC (1991) Rat liver outer mitochondrial carnitine palmitoyltransferase activity towards long-chain polyunsaturated fatty acids and their CoA esters. *Lipids* **26**, 266–270.
8. Leyton J, Drury PJ & Crawford MA (1987) Differential oxidation of saturated and unsaturated fatty acids *in vivo* in the rat. *Br J Nutr* **57**, 383–393.
9. Plourde M & Cunnane SC (2007) Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Appl Physiol Nutr Metab* **32**, 619–634.
10. Skeaff CM & Miller J (2009) Dietary fat and coronary heart disease: summary of evidence from prospective cohort and randomised controlled trials. *Ann Nutr Metab* **55**, 173–201.
11. Innis SM (2007) Dietary (n-3) fatty acids and brain development. *J Nutr* **137**, 855–859.
12. Cunnane SC, Plourde M, Pifferi F *et al.* (2009) Fish, docosahexaenoic acid and Alzheimer's disease. *Prog Lipid Res* **48**, 239–256.
13. Yaffe K (2010) Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. *JAMA* **304**, 1952–1953.
14. Mazereeuw G, Lanctot KL, Chau SA *et al.* (2012) Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. *Neurobiol Aging* **33**, 1482, e1417–e1429.
15. Sydenham E, Dangour AD & Lim WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database Syst Rev* **6**, CD005379.
16. Stonehouse W, Conlon CA, Podd J *et al.* (2013) DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. *Am J Clin Nutr* **97**, 1134–1143.
17. Yurko-Mauro K, McCarthy D, Rom D *et al.* (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimers Dement* **6**, 456–464.
18. Sinn N, Milte CM, Street SJ *et al.* (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *Br J Nutr* **107**, 1682–1693.
19. Quinn JF, Raman R, Thomas RG *et al.* (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1903–1911.
20. Fotuhi M, Mohassel P & Yaffe K (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. *Nat Clin Pract Neurol* **5**, 140–152.
21. Barberger-Gateau P, Feart C, Letenneur *et al.* (2013) Dietary patterns and dementia. In *Chronic Medical Disease and Cognitive Aging: Toward a Healthy Body and Brain* pp. 197–224 [Yaffe K, editor]. United States: Oxford University Press.
22. Kim HY, Akbar M & Kim YS (2010) Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. *Prostaglandins Leukot Essent Fatty Acids* **82**, 165–172.
23. Bazan NG, Molina MF & Gordon WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. *Annu Rev Nutr* **31**, 321–351.
24. Sidhu VK, Huang BX & Kim HY (2011) Effects of docosahexaenoic acid on mouse brain synaptic plasma membrane proteome analyzed by mass spectrometry and (16)O/(18)O labeling. *J Proteome Res* **10**, 5472–5480.
25. Calon F & Cole G (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. *Prostaglandins Leukot Essent Fatty Acids* **77**, 287–293.
26. Boudrault C, Bazinet RP & Ma DW (2009) Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. *J Nutr Biochem* **20**, 1–10.
27. Barberger-Gateau P, Samieri C, Feart C *et al.* (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. *Curr Alzheimer Res* **8**, 479–491.
28. Brenna JT & Diau GY (2007) The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. *Prostaglandins Leukot Essent Fatty Acids* **77**, 247–250.
29. Oster T & Pillot T (2010) Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. *Biochimica et Biophysica Acta – Mol Cell Biol Lipids* **1801**, 791–798.
30. Connor WE, Neuringer M & Reischick S (1991) Essentiality of omega 3 fatty acids: evidence from the primate model and implications for human nutrition. *World Rev Nutr Diet* **66**, 118–132.
31. Novak EM, Dyer RA & Innis SM (2008) High dietary omega-6 fatty acids contribute to reduced docosahexaenoic

- acid in the developing brain and inhibit secondary neurite growth. *Brain Res* **1237**, 136–145.
32. Soderberg M, Edlund C, Kristensson K *et al.* (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. *Lipids* **26**, 421–425.
 33. Lukiw WJ, Cui JG, Marcheselli VL *et al.* (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. *J Clin Invest* **115**, 2774–2783.
 34. Arsenault LN, Matthan N, Scott TM *et al.* (2009) Validity of estimated dietary eicosapentaenoic acid and docosahexaenoic acid intakes determined by interviewer-administered food frequency questionnaire among older adults with mild-to-moderate cognitive impairment or dementia. *Am J Epidemiol* **170**, 95–103.
 35. Astarita G, Jung KM, Berchtold NC *et al.* (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. *PLoS ONE* **5**, e12538.
 36. Boston PF, Bennett A, Horrobin DF *et al.* (2004) Ethyl-EPA in Alzheimer's disease—a pilot study. *Prostaglandins Leukot Essent Fatty Acids* **71**, 341–346.
 37. Brooksbank BW & Martinez M (1989) Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease. *Mol Chem Neuropathol* **11**, 157–185.
 38. Cherubini A, Andres-Lacueva C, Martin A *et al.* (2007) Low plasma N-3 fatty acids and dementia in older persons: The InCHIANTI study. *J Gerontol A, Biol Sci Med Sci* **62**, 1120–1126.
 39. Conquer JA, Tierney MC, Zecevic J *et al.* (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. *Lipids* **35**, 1305–1312.
 40. Corrigan FM, Van Rhijn AG, Ijomah G *et al.* (1991) Tin and fatty acids in dementia. *Prostaglandins Leukot Essent Fatty Acids* **43**, 229–238.
 41. Corrigan FM, Horrobin DF, Skinner ER *et al.* (1998) Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. *Int J Biochem Cell Biol* **30**, 197–207.
 42. Cunnane S, Schneider J, Tangney C *et al.* (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. *J Alzheimer's Dis* **29**, 691–697.
 43. Fraser T, Tayler H & Love S (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. *Neurochem Res* **35**, 503–513.
 44. Guan Z, Wang Y, Cairns NJ *et al.* (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. *J Neuropathol Exp Neurol* **58**, 740–747.
 45. Laurin D, Verreault R, Lindsay J *et al.* (2003) Omega-3 fatty acids and risk of cognitive impairment and dementia. *J Alzheimer's Dis* **5**, 315–322.
 46. Prasad MR, Lovell MA, Yatin M *et al.* (1998) Regional membrane phospholipid alterations in Alzheimer's disease. *Neurochem Res* **23**, 81–88.
 47. Selley ML (2007) A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. *Neurobiol Aging* **28**, 1834–1839.
 48. Skinner ER, Watt C, Besson JA *et al.* (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. *Brain* **116**(Pt 3), 717–725.
 49. Tully AM, Roche HM, Doyle R *et al.* (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. *Br J Nutr* **89**, 483–489.
 50. Svennerholm L, Boström K & Jungbjer B (1997) Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. *Acta Neuropathol* **94**, 345–352.
 51. Aizenstein HJ, Nebes RD, Saxton JA *et al.* (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol* **65**, 1509–1517.
 52. Braak H & Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* **18**, 351–357.
 53. Duyckaerts C & Hauw JJ (1997) Prevalence, incidence and duration of Braak's stages in the general population: can we know? *Neurobiol Aging* **18**, 362–369; discussion 389–392.
 54. Umhau JC, Zhou W, Carson RE *et al.* (2009) Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. *J Lipid Res* **50**, 1259–1268.
 55. Chen CT, Green JT, Orr SK *et al.* (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. *Prostaglandins Leukot Essent Fatty Acids* **79**, 85–91.
 56. Serhan CN & Petasis NA (2011) Resolvins and protectins in inflammation resolution. *Chem Rev* **111**, 5922–5943.
 57. Cunnane SC, Chouinard-Watkins R, Castellano CA *et al.* (2013) Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: can we reconcile the evidence? *Prostaglandins Leukot Essent Fatty Acids* **88**, 61–70.
 58. Wang DC, Sun CH, Liu LY *et al.* (2012) Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. *Neurobiol Aging* **33**, 1057–1066.
 59. Ronnema E, Zethelius B, Vessby B *et al.* (2012) Serum fatty-acid composition and the risk of Alzheimer's disease: a longitudinal population-based study. *Eur J Clin Nutr* **66**, 885–890.
 60. Heude B, Ducimetiere P & Berr C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes—the EVA Study. *Am J Clin Nutr* **77**, 803–808.
 61. Schaefer EJ, Bongard V, Beiser AS *et al.* (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. *Arch Neurol* **63**, 1545–1550.
 62. Kroger E, Verreault R, Carmichael PH *et al.* (2009) Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. *Am J Clin Nutr* **90**, 184–192.
 63. Dullemeijer C, Durga J, Brouwer IA *et al.* (2007) n 3 fatty acid proportions in plasma and cognitive performance in older adults. *Am J Clin Nutr* **86**, 1479–1485.
 64. Beydoun MA, Kaufman JS, Satia JA *et al.* (2007) Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. *Am J Clin Nutr* **85**, 1103–1111.
 65. Whalley LJ, Deary IJ, Starr JM *et al.* (2008) n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. *Am J Clin Nutr* **87**, 449–454.
 66. Samieri C, Fear C, Proust-Lima C *et al.* (2011) omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. *Neurobiol Aging* **32**, 2317, e2313–e2322.
 67. Plourde M, Chouinard-Watkins R, Vandal M *et al.* (2011) Plasma incorporation, apparent retroconversion and

- beta-oxidation of ¹³C-docosahexaenoic acid in the elderly. *Nutr Metab (Lond)* **8**, 5.
68. Vandal M, Freemantle E, Tremblay-Mercier J *et al.* (2008) Plasma omega-3 fatty acid response to a fish oil supplement in the healthy elderly. *Lipids* **43**, 1085–1089.
 69. Millar JS, Lichtenstein AH, Cuchel M *et al.* (1995) Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. *J Lipid Res* **36**, 1155–1167.
 70. Jack CR Jr, Knopman DS, Jagust WJ *et al.* (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* **9**, 119–128.
 71. Jack CR Jr, Petersen RC, Xu YC *et al.* (1998) Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. *Ann Neurol* **43**, 303–310.
 72. Chouinard-Watkins R, Rioux-Perreault C, Fortier M *et al.* (2013) Disturbance in uniformly ¹³C-labelled docosahexaenoic acid metabolism in elderly humans carrying apolipoprotein E epsilon 4 allele. *Br J Nutr* **30**, 1–9.
 73. Plourde M, Vohl MC, Vandal M *et al.* (2009) Plasma *n*-3 fatty acid response to an *n*-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. *Br J Nutr* **102**, 1121–1124.
 74. Huang TL, Zandi PP, Tucker KL *et al.* (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. *Neurology* **65**, 1409–1414.
 75. Barberger-Gateau P, Raffaitin C, Letenneur L *et al.* (2007) Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* **69**, 1921–1930.
 76. Harris WS, Mozaffarian D, Lefevre M *et al.* (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. *J Nutr* **139**, 804S–819S.
 77. Kris-Etherton PM, Grieger JA & Etherton TD (2009) Dietary reference intakes for DHA and EPA. *Prostaglandins Leukot Essent Fatty Acids* **81**, 99–104.
 78. Meyer BJ (2011) Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? *Prostaglandins Leukot Essent Fatty Acids* **85**, 275–280.
 79. Sanders TA, Hinds A & Pereira CC (1989) Influence of *n*-3 fatty acids on blood lipids in normal subjects. *J Intern Med Suppl* **731**, 99–104.
 80. James MJ, Ursin VM & Cleland LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other *n*-3 fatty acids. *Am J Clin Nutr* **77**, 1140–1145.
 81. Fokkema MR, Brouwer DA, Hasperhoven MB *et al.* (2000) Short-term supplementation of low-dose gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. *Prostaglandins Leukot Essent Fatty Acids* **63**, 287–292.
 82. Horrobin D, Fokkema MR & Muskiet FA (2003) The effects on plasma, red cell and platelet fatty acids of taking 12 g/day of ethyl-eicosapentaenoate for 16 months: dihomogammalinolenic, arachidonic and docosahexaenoic acids and relevance to Inuit metabolism. *Prostaglandins Leukot Essent Fatty Acids* **68**, 301–304.
 83. Lopez LB, Kritz-Silverstein D & Barrett Connor E (2011) High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo study. *J Nutr Health Aging* **15**, 25–31.